Open AccessClinical characteristics and pathogens in percutaneous endoscopic gastrostomy site infection in patients with head and neck cancer: A 16‐year retrospective study
Author(s) -
Oh Jihyu,
Park So Yeon,
Lee Jin Seo,
Park JiYoung,
Lee Seo Hu
Publication year - 2021
Publication title -
laryngoscope investigative otolaryngology
Language(s) - English
Resource type - Journals
ISSN - 2378-8038
DOI - 10.1002/lio2.666
Subject(s) - medicine , percutaneous endoscopic gastrostomy , head and neck cancer , peg ratio , pseudomonas aeruginosa , cancer , surgery , retrospective cohort study , incidence (geometry) , complication , antibiotics , gastroenterology , microbiology and biotechnology , biology , physics , finance , bacteria , optics , economics , genetics
Objectives Wound infection is the most common complication associated with percutaneous endoscopic gastrostomy (PEG) placement, with an incidence between 4% and 30%. In this study, we compared the characteristics of PEG site infection between the head and neck cancer (HNC) group and the non‐HNC group. Methods This study was conducted at Kangdong Sacred Heart Hospital at the Ilsong Head and Neck Cancer Center. We retrospectively collected and analyzed data on patients who underwent PEG insertion from October 2003 to May 2019 to evaluate the risk factors and microbiological etiologies of PEG site infection. Results A total of 316 (HNC group [n = 129] and non‐HNC group [n = 187]) patients undergoing PEG insertion were included in this study. Moreover, 67 episodes of PEG site infection were diagnosed, with an overall prevalence of 21.2%. PEG site infections were significantly higher in the HNC group than in the non‐HNC group (32.6% vs 13.4%, P <.001). Pseudomonas aeruginosa is the most common pathogen associated with a PEG site infection. Multidrug‐resistant (MDR) P aeruginosa was more frequent in the HNC group than in the non‐HNC group (78.6% vs 25.0%, P = .006). Conclusions For appropriate treatment, P aeruginosa , especially MDR P aeruginosa , should be considered when selecting empirical antibiotics for PEG site infection in patients with HNC. Level of Evidence: 4